Get started
HALOZYME THERAPEUTHALOZYME THERAPEUTHALOZYME THERAPEUT

HALOZYME THERAPEUT

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Forecast Seasonals Bonds

RV7 chart


Full chart

RV7 upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪5.39 B‬ CHF
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
15.234
Basic EPS (TTM)
2.611 CHF
Net income (FY)
‪237.08 M‬ CHF
Revenue (FY)
‪698.18 M‬ CHF
Shares float
‪125.88 M‬
Beta (1Y)
1.42

Employees


Employees (FY)
373
Change (1Y)
−20 −5.09%
Revenue / Employee (1Y)
‪1.87 M‬ CHF
Net income / Employee (1Y)
‪635.61 K‬ CHF

About Halozyme Therapeutics, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Helen I. Torley
Website
halozyme.com
Headquarters
San Diego
Founded
1998
FIGI
BBG00LVDJMV7
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

RV7 news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

RV7 highest yielding bonds


HALO5387960
Halozyme Therapeutics, Inc. 0.25% 01-MAR-2027
Yield to maturity
2.91%
Maturity date
Mar 1, 2027
HALO5638653
Halozyme Therapeutics, Inc. 1.0% 15-AUG-2028
Yield to maturity
−1.10%
Maturity date
Aug 15, 2028

Explore more bonds 

Sparks


Curated watchlists where RV7 is featured.

See all sparks 

Frequently Asked Questions


The current price of RV7 is 42.513 CHF — it has increased by 2.70% in the past 24 hours. Watch HALOZYME THERAPEUT stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange HALOZYME THERAPEUT stocks are traded under the ticker RV7.
RV7 stock has risen by 2.70% compared to the previous week, the month change is a 2.70% rise, over the last year HALOZYME THERAPEUT has showed a 22.08% increase.
We've gathered analysts' opinions on HALOZYME THERAPEUT future price: according to them, RV7 price has a max estimate of 67.02 CHF and a min estimate of 46.47 CHF. Watch RV7 chart and read a more detailed HALOZYME THERAPEUT stock forecast: see what analysts think of HALOZYME THERAPEUT and suggest that you do with its stocks.
RV7 reached its all-time high on Sep 2, 2024 with the price of 53.851 CHF, and its all-time low was 30.464 CHF and was reached on Dec 7, 2021. View more price dynamics on RV7 chart.
See other stocks reaching their highest and lowest prices.
RV7 stock is 2.63% volatile and has beta coefficient of 1.42. Track HALOZYME THERAPEUT stock price on the chart and check out the list of the most volatile stocks — is HALOZYME THERAPEUT there?
Today HALOZYME THERAPEUT has the market capitalization of ‪5.45 B‬, it has decreased by −0.81% over the last week.
Yes, you can track HALOZYME THERAPEUT financials in yearly and quarterly reports right on TradingView.
HALOZYME THERAPEUT is going to release the next earnings report on Feb 25, 2025. Keep track of upcoming events with our Earnings Calendar.
RV7 earnings for the last quarter are 1.08 CHF per share, whereas the estimation was 0.84 CHF resulting in a 28.12% surprise. The estimated earnings for the next quarter are 1.03 CHF per share. See more details about HALOZYME THERAPEUT earnings.
HALOZYME THERAPEUT revenue for the last quarter amounts to ‪245.83 M‬ CHF, despite the estimated figure of ‪213.70 M‬ CHF. In the next quarter, revenue is expected to reach ‪259.86 M‬ CHF.
RV7 net income for the last quarter is ‪116.11 M‬ CHF, while the quarter before that showed ‪83.83 M‬ CHF of net income which accounts for 38.50% change. Track more HALOZYME THERAPEUT financial stats to get the full picture.
No, RV7 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has 373.00 employees. See our rating of the largest employees — is HALOZYME THERAPEUT on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. HALOZYME THERAPEUT EBITDA is ‪473.40 M‬ CHF, and current EBITDA margin is 50.94%. See more stats in HALOZYME THERAPEUT financial statements.
Like other stocks, RV7 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade HALOZYME THERAPEUT stock right from TradingView charts — choose your broker and connect to your account.